Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Trust Investment Advisors

Trust Investment Advisors reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 11,683 shares of the medical research company’s stock after selling 559 shares during the quarter. Trust Investment Advisors’ holdings in Edwards Lifesciences were worth $865,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of EW. Avior Wealth Management LLC increased its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. Advisors Asset Management Inc. grew its position in shares of Edwards Lifesciences by 7.7% in the 3rd quarter. Advisors Asset Management Inc. now owns 11,856 shares of the medical research company’s stock worth $782,000 after acquiring an additional 852 shares in the last quarter. Eagle Asset Management Inc. increased its holdings in shares of Edwards Lifesciences by 38.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 30,282 shares of the medical research company’s stock valued at $2,006,000 after acquiring an additional 8,346 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $303,000. Finally, Larson Financial Group LLC lifted its stake in Edwards Lifesciences by 199.1% during the third quarter. Larson Financial Group LLC now owns 4,391 shares of the medical research company’s stock worth $290,000 after purchasing an additional 2,923 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,303 shares of company stock valued at $3,715,776 in the last quarter. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $71.29 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market capitalization of $41.91 billion, a price-to-earnings ratio of 10.23, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business has a 50 day moving average price of $71.43 and a two-hundred day moving average price of $70.45. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Piper Sandler increased their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.